Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab transcriptomic predictor study in moderately to severely active ulcerative colitis
NL-OMON40782Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of golimumab in autoimmune colitis, sponsored by Janssen Pharmaceutical. Started Mar 2014; status: active, not recruiting.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON40782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40782.